The cost:benefit ratio of acute intervention for myocardial infarction: Results of a prospective, matched pair analysis
- 1 November 1989
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 118 (5), 878-882
- https://doi.org/10.1016/0002-8703(89)90217-2
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- THROMBOLYSIS WITH TISSUE PLASMINOGEN ACTIVATOR IN ACUTE MYOCARDIAL INFARCTION: NO ADDITIONAL BENEFIT FROM IMMEDIATE PERCUTANEOUS CORONARY ANGIOPLASTYThe Lancet, 1988
- A Randomized Trial of Intravenous Tissue Plasminogen Activator for Acute Myocardial Infarction with Subsequent Randomization to Elective Coronary AngioplastyNew England Journal of Medicine, 1987
- A cost-effectiveness model for coronary thrombolysis/reperfusion therapyJournal of the American College of Cardiology, 1987
- Effect of Intravenous Streptokinase on Left Ventricular Function and Early Survival after Acute Myocardial InfarctionNew England Journal of Medicine, 1987
- Angioplasty in Acute Myocardial InfarctionNew England Journal of Medicine, 1987
- A Randomized Trial of Immediate versus Delayed Elective Angioplasty after Intravenous Tissue Plasminogen Activator in Acute Myocardial InfarctionNew England Journal of Medicine, 1987
- A Prospective Trial of Intravenous Streptokinase in Acute Myocardial Infarction (I.S.A.M.)New England Journal of Medicine, 1986
- IMPROVED SURVIVAL AFTER EARLY THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1985
- The Thrombolysis in Myocardial Infarction (TIMI) TrialNew England Journal of Medicine, 1985
- Institutional Responses to Prospective Payment Based on Diagnosis-Related GroupsNew England Journal of Medicine, 1985